Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors

PURPOSE: Anaplastic lymphoma kinase (ALK) rearrangement is a well-known driver oncogene in non–small-cell lung cancer and has also been identified in other types of tumors. However, there is limited evidence on the clinical response to ALK tyrosine kinase inhibitors (TKIs), such as alectinib and cri...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeyasu, Yuki, Okuma, Hitomi S., Kojima, Yuki, Nishikawa, Tadaaki, Tanioka, Maki, Sudo, Kazuki, Shimoi, Tatsunori, Noguchi, Emi, Arakawa, Ayumu, Mori, Taisuke, Sunami, Kuniko, Kubo, Takashi, Kohno, Takashi, Akihiko, Yoshida, Yamamoto, Noboru, Yonemori, Kan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140781/
https://www.ncbi.nlm.nih.gov/pubmed/34036223
http://dx.doi.org/10.1200/PO.20.00383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140781/
https://www.ncbi.nlm.nih.gov/pubmed/34036223
http://dx.doi.org/10.1200/PO.20.00383

Ejemplares similares